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The combination of microfabrication-based technologies with cell biology has laid the
foundation for the development of advanced in vitro diagnostic systems capable of
evaluating cell cultures under defined, reproducible, and standardizable measurement
conditions. In the present review, we describe recent lab-on-a-chip developments for
cell analysis and how these methodologies could improve standard quality control in
the field of manufacturing cell-based vaccines for clinical purposes. We highlight in
particular the regulatory requirements for advanced cell therapy applications using as
an example dendritic cell-based cancer vaccines to describe the tangible advantages of
microfluidic devices that overcome most of the challenges associated with automation,
miniaturization, and integration of cell-based assays. As its main advantage, lab-on-a-chip
(LoC) technology allows for precise regulation of culturing conditions, while simultaneously
monitoring cell relevant parameters using embedded sensory systems. State-of-the-art
lab-on-a-chip platforms for in vitro assessment of cell cultures and their potential future
applications for cell-based strategies for cancer immunotherapy are discussed in the
present review.
Keywords: microfluidics, lab-on-a-chip, immunoassay, automation, quality control, cell therapy, FACS, ATMP
1. Cell-Based Strategies for Cancer Immuno-Therapy
In recent years, cell therapies have been recognized as an important alternative to conventional
medical care to alleviate human diseases. Cell therapy, defined as the treatment in which cells
are injected into a patient, can be divided into mesenchymal stem cell therapy, hematopoietic
stem cell transplantation, and allogeneic or autologous cell therapy (Gage, 1998). Over the past
decades, cell therapy treatments have predominantly been applied in cancer immunotherapy (CIT)
to control tumor growth and metastasis (Finn, 2003), following the specific activation of immune
cells against tumors. In the case of adoptive, allogeneic cell therapy activation of the immune
system is accomplished by passive immunization through transfusion of cytotoxic T cells into the
patient. Over the years, various immune cell types have been employed for CIT, including natural
killer T cells (NKT cells), lymphokine-activated killer cells (LAK cells), cytotoxic T lymphocytes
(CTLs), and dendritic cells (DCs) (Zigler et al., 2013). Among these, cytotoxic T cells and DCs are
at the forefront of cancer immunotherapies where immune cell activation can either be induced
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ex vivo or in vivo. Commonly usedmethods for ex vivo generation
of cytotoxic T cells for anti-cancer treatment are based on the
isolation of primary peripheral blood mononuclear cells (PBMC)
followed by expansion and stimulation/activation of T cells. T
cell stimulation can be achieved using anti-CD3/anti-CD28 mon-
oclonal antibodies immobilized on planar substrates (Yamada-
Ohnishi et al., 2004), artificial antigen-presenting cells, such as
HLA-Ig-coated beads (Oelke et al., 2003) and paramagnetic anti-
CD3/anti-CD28-coated beads (Trickett andKwan, 2003). Alterna-
tively, DC-based active cancer immunotherapy is based on ex vivo
generation of “professional” antigen-presenting cells (APCs) that
are able to offer specific tumor antigens to lymphocytes in vivo.
One key features of matured antigen-presenting DCs for active
cancer immunotherapy are their increased expression of MHC
class II and co-stimulatory molecules as well as their ability to
secrete cytokines, such as IL12, that enable recruitment and acti-
vation of cytotoxic antigen-specific CD8+ CTLs. A comparison
between passive and active cancer immunotherapy is provided in
Table 1.
In addition to the Nobel prize in Physiology and Medicine
awarded in 2011 for discovery of DCs role in the immune sys-
tem, latest advances in DC-based cancer immunotherapy were
recently selected by Science as the breakthrough of the year 2013
(Couzin-Frankel, 2013). An advantage of DC-based therapeutic
vaccines over passive immunotherapy strategies is the inherent
ability of DC to prime naïve T cells and also expand memory
T cells, which ultimately leads to the generation of a long-lived
immune response capable of preventing tumor relapse (Kalinski
et al., 2013). Although cancer immunotherapies are considered
superior over conventional chemotherapy in terms of natural
selectivity, specificity, and memory effect, a range of potential
complications may still occur. For instance, immune-mediated
therapies, which are priming the immune system to target tumors
expressing certain tumor-associated antigens (TAA), may also
induce a response to antigens that are expressed by normal tissues
(Hung et al., 2008; Criscitiello, 2012). Potential safety concerns
with DC-based cancer vaccines may further include local inflam-
matory reactions, systemic toxicity, and adverse effects on the
host immune system, such as autoimmune responses caused by
impurities, contaminants, or other components of the vaccine
formulation (Kalantari et al., 2011). As a consequence, it is impor-
tant to evaluate the safety, mechanism of action and efficacy of
immune-mediated therapies. Accordingly, therapeutic vaccina-
tions intended for treatment of cancer must be evaluated on its
safety and clinical efficacy for both active and passive products.
It is also important to note that clinical efficacy evaluations are
compulsory for all pharmaceutical products based on living, func-
tional cells that mediate therapeutic effects, including Alzheimers
disease, Parkinsons disease, cardiovascular disorder, and autoim-
mune disease (Martínez-Morales et al., 2013). These include a
large number of biotechnology and pharmaceutical industries,
which are involved in several clinical trials using DC, NKT cells,
and lymphocytes aswell as stem cells derived fromblood and bone
marrow, liver, etc., to treat structural, metabolic, genetic, neuro-
logic, orthopedic, and cardiovascular disorders. The status and
outcome of current clinical trials involving safety of immunother-
apeutic products, such as cancer vaccines, can be found at www.
clinicaltrials.gov, where currently 797 studies in phase II
and 787 studies in phase III are listed. Among these trials, several
led to immune responses that are associated with overall survival
(Kantoff and Higano, 2010; Walter et al., 2012) and disease-free
survival (Schuster et al., 2011).
2. Regulatory Aspects and Quality Control
Measures of Advance Therapy Medicinal
Products
In all instances, themanufacturing process and biologicalmaterial
characteristics of the employed cell therapy must be rigorously
controlled and demonstrated to be consistent with product spec-
ifications. This means that the manufacturing process of living,
functional cells needs strict regulations based on validated meth-
ods andprocedures. The threemost important regulatory agencies
responsible for the evaluation and supervision of medicines for
human use are European Medicines Agency (EMA) in the Euro-
pean Union (EU), Food and Drug Administration (FDA) in the
USA, and Ministry of Health, Labor and Welfare (MHLW) in
Japan. Harmonization between these agencies is achieved through
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH), which develops guidelines for quality, efficacy and
safety of advanced therapy medicinal products (ATMP) (Dixon,
1999; ICH, 2015). In Europe, ATMP are further controlled by the
Regulation (EC) No. 1394/2207 (Antunes and Pottering, 2007),
which defines requirements of quality, efficacy, and safety for
administration in humans. Consequently, good manufacturing
practice (GMP) standards have to be applied for both produc-
tion and quality control ensuring that medicinal products are
consistently produced and controlled to the quality standards
TABLE 1 | Comparison of cancer immunotherapies.
Types of cancer immunotherapy Characteristics
Active immunotherapy Stimulates host immune system Cell-based immunotherapy Cancer vaccines DCs
Durable response Non-cellular products Interleukins, adjuvants
Passive immunotherapy Enhance pre-existing immune response Immune modulators Antibodies
Receptors
Cytokines
Checkpoint inhibitors
No memory: chronic administration Cell-based immunotherapy Adoptive cellular immunotherapy T cells
B cells
NK cells
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appropriate to their intended use and according to the require-
ments of the product specification (Alici and Blomberg, 2010).
The quality criteria required by the European and American reg-
ulations for biological product characterization are based on tests
for sterility, identity of the cellular and non-cellular components,
purity, viability, potency, and reproducibility (Agency, 2007). A
detailed description of product requirements is listed in Table 2.
As an example, flow cytometry (FACS) and ELISA techniques
have been extensively used to assess the expression density of
functionally important cell membrane molecules and the amount
of secretedmolecules, such as interleukins, IFN-γ, IL-4, granzyme,
perforin, and others. These tests need to provide information on
an immune cells functional capacity, subset distribution, purity,
viability, cytolytic immunity, and capacity to stimulate T-cells and
attack target cancer cells.
3. Automation and Miniaturization of
Cell-Based Assays for Quality Control
Automation is the most straightforward strategy for assuring a
maximum of reproducibility, which is also a core request of
regulators. It is also important to highlight that quality control
(QC) of personalized cancer vaccines is by far the more labor
intensive procedure in comparison to cell manufacturing, which
has essentially become an engineering task (Hinz et al., 2006).
Although robotic cell culture systems have been available since
about 20 years (Sharma et al., 2011), to date no technological
solution exists that allows for automation and miniaturization of
QC measures to ensure product safety by simultaneously reduc-
ing manual labor steps, material costs, as well as sample and
media requirement. Although recent advances in lab automation
have brought several high throughput systems for automated cell
culture analysis to themarket, the applicability of these automated
cell analysers for personalized medicine is still questionable.
These commercially available automation standards are mainly
based on the application of existing fluid handling systems for
microtiter-plate technologies in combination with incubators,
robotics, and external optical imaging systems. Table 3 lists a
number of automated cell analysers developed for modern clin-
ical laboratory environments. The main challenges with adapting
these systems to quality control for immune cell therapy products
are their inherent small sample volume requirements, expen-
sive clinical grade reagents necessary to characterize cell pheno-
types, and time-resolved analysis of cell population responses.
Other drawbacks of existing automated cell analyser systems are
their time consuming and expensive cell staining procedures that
include endpoint detection methods to identify cell phenotypes
(Kramer et al., 2013). End-point detection methods also often
underestimate labeling artifacts and require complex handling
steps and multiple reagents leading to low reproducibility and
accuracy (Michelini et al., 2010). In this context, lab-on-a-chip
(LoC) technology has the potential to provide the next generation
of cell analysis tools capable of inexpensively testing large numbers
of single cells or small numbers of cell populations under con-
trolled and reproducible measurement conditions (Whitesides,
2006). Cell chips have initially been used to count and analyze cells
inminiaturized flow cytometers which are commercially available
today (e.g., Agilent 2100 bioanalyser) (McClain et al., 2001). More
recently, microfluidic devices for cellular studies have been devel-
oped to investigate cell transport and cultivation in the absence
and presence of concentration and temperature gradients or shear
force conditions (Andersson and van den Berg, 2003). Overall,
microfluidic systems have been used to perform cell sampling,
cell trapping, sorting, patterning, treatment, and multi-parameter
cell analysis under a defined set of conditions (Vilkner et al.,
2004; Yi et al., 2006a,b; Charwat and Muellner, 2011; Charwat
et al., 2013a,b; Ungerböck et al., 2013). The application of cell chip
technology for automated quality control measures has therefore
TABLE 2 | Guidelines and definition of product quality.
Sterility The absence of contaminating agents (bacteria, fungal, and viral) and low endotoxin level should be ensured in cell-based medical products. Quality of
biologically active additives in culture media, such as growth factors, cytokines, and antibodies, should be documented with respect to identity, purity,
sterility, and biological activity and absence of accidental agents. Mycoplasma testing should be also performed if the product includes cell culture of
more than 24 h
Identity The identity of the cellular components, depending on the cell population and origin, should be characterized in terms of phenotypic and genotypic
profiles. When identifying the phenotype of the cells, relevant markers should be used. Several cellular markers indicative of cell type, differentiation,
and/or assays of functionality can be used to establish identity
Purity Purity of the cell-based product relates to the minimization of undesirable contaminants, such as unintended cell population (e.g., distinguished by
phenotype), non-cellular impurities that may have been introduced during the manufacturing process and cell debris that are not required for the
overall function of the medicinal product. As a result, the aim should be to maximize the active components and minimize features that do not
contribute, or may negatively impact on therapeutic activity/safety. The appropriate purity specifications will be established from characterization
studies conducted as part of product development and by the selection of appropriate in-process controls and release tests
Viability Irrespective of cell type, the cell population can be contaminated with non-viable cells. Since cell viability is an important parameter for product integrity
and is directly correlated to the biologic activity, the ratio between non-viable and viable cells should be determined and specifications should be set.
FDAs guidelines recommend that this specification be set at least 70%
Potency The design of a potency assay can vary depending on the product and it may comprise both functional tests and marker-based assays. Ideally, the
assay should be at least semi-quantitative. Examples of biological activity/potency include:
 expression of relevant biological substances (e.g., recombinant protein, glyco- or lipo-protein, growth factors, enzymes, cytokines);
 formation of cell/extra cellular matrix/structures;
 cell interactions (e.g., immune activation/inhibition);
 measurements of differentiation/self-renewing capacity/migration
Reproducibility Issues of the manufacturing process reproducibility are of importance for an individually manufactured medicament. To ensure the robustness of the
manufacturing process, the level of automation plays a critical role in assuring the reproducibility of medicinal product manufacturing
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TABLE 3 | Companies offering miniaturized cell analysis systems.
Company Products Field of Research Website
Acea Bioscience Microelectronic systems for cell-based assays Instrumentation for life sciences aceabio.com
Bartels Mikrotechnik Microfluidic components: micropomps, microvalves Applications for microsystems bartels-mikrotechnik.de
CapitalBio Corporation Biochip-based microelectronic for cell electrophysiology Diagnostics, instruments capitalbio.com
CEA Laboratory of Electronics
and Information Technologies
DNA-chips; lab-on-a-chip devices and microsystems for cells
analysis
Diagnostics, research instruments cea.fr
Cytoo Chips for micropatterned cell culture Research instruments cytoo.com
LabSmith Microfluidic components Applications for microsystems labsmith.com
MicroTec MEMS, microsystems and components, micromechanics for
cell disruption, micro-arrays, micro titer plates
Development, microsystems
technology, manufacturing
microtec-d.com
NanoCellect μFACS, microfluidics technology for cells sorting Diagnostics, R&D instruments nanocellect.com
Nanomix Lab-on-chip point of care diagnostics Diagnostics nano.com
Nanopoint Imaging Microfluidics platforms for reproductive technology, drug
discovery, cell culturing
Research instruments nanopointimaging.com
NanoEntek Microdevices for life sciences research and diagnostics,
including automatic cell counters, gene transfection
electroporators, and point-of-care diagnostics
Research instruments nanoentek.com
Siloam Biosciences Point-of-care clinical diagnostic systems using microfluidic and
microsensor technology
Diagnostic siloambio.com
Sphere Fluidics Commercializing lab-on-a-chip and picodroplet technology Research instruments spherefluidics.com
FIGURE 1 | Overview over the historical development of lab-on-a-chip technology for cell-based assays.
the potential to close the existing product-gap by providing
fully automated and miniaturized analysis systems with improved
reproducibility for (a) assuring compliancewith specifications, (b)
reduction of hand-on work and corresponding human errors, and
(c) reduced usage of expensive clinical grade biological reagents.
The minimum requirements for cell chip technology to per-
form as a quality control measure for cell-based systems is
the miniaturization, integration, and automation of crucial cell
culture operations, such as liquid handling, proper cell cul-
ture, biosensing, as well as phenotype/secretome analysis within
a single microdevice. Precise spatio-temporal control over the
cellular microenvironment (e.g., physical and chemical stimu-
lation) is mandatory for proper cell propagation (Oelke et al.,
2003; Trickett and Kwan, 2003; Yamada-Ohnishi et al., 2004) as
well as maintenance of cell phenotypes (Gallucci et al., 1999;
Kodaira et al., 2000; Lewis et al., 2013). The integration of in-
line biosensors enables dynamic and time-resolved monitoring of
cell cultures during all stages of the production process of cell-
based therapies in a non-destructive manner. Last but not least,
automation andminiaturization of state-of-the-art quality control
assays for monitoring of metabolites and cell phenotypes enable
high-throughput analysis with reduction of manual labor.
The following three subsections focus on fundamental ele-
ments, which enable the microfabrication of chip-based quality
control platforms, including fabrication methods and materials,
liquid handling systems, and biosensing strategies for cell-based
applications.
3.1. Fabrication Methods and Materials of Cell
Chip Systems
Although studying in vitro cell cultures is an essential aspect of cell
biology, its technological advancement has lagged behind com-
pared with progress made in the fields of genomics, proteomics,
and high-throughput testing of biochemicals. In this context,
microfabrication technology has the potential to provide the next
generation of cell analysis tools capable of inexpensively testing a
large number of single cells or a small number of cell populations
in environments of increased physiological relevance (Whitesides,
2003; Ionescu-Zanetti et al., 2005). Biochip technology is vital for
cell analysis because it is capable of providing answers to dynamic
and rapidly changing biological systems using label-free analytics
and microfluidics (El-Ali et al., 2006). As seen in Figure 1 lab-on-
a-chip and cell chip technology stems from semi-conductor fab-
rication technologies with the first microfluidic chips fabricated
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in the late 1980s. Later in 1993, Harrison and Manz achieved
a large technological leap with on-chip capillary electrophoresis
(Harrison et al., 1993). However, with the introduction of soft
lithography by Xia and Whitesides 1998, biologists started to
adapt these integrated microsystems for cell manipulation and
analysis with the first dedicated journal lab-on-a-chip initiated
in 2001 (Xia and Whitesides, 1998). In 2004, Michael Shuler and
colleagues introduced micromachining techniques to fabricate
multi-compartment cell culture systems in which microfluidic
channels control fluid flow between the single tissue compart-
ments (Sin et al., 2004). These microdevices, also known as micro
cell culture analog (μCCA), animal-on-a-chip and body-on-a-
chip, simulate the complex interplay between multiple organ and
tissue types with a functional circulatory system. From that point
on the development of highly complex cell-chip devices that
incorporate micropumps and valves, mixers, actuators, degassers,
biosensors, as well as multiple cell cultivation chambers for multi-
plexed cell analysis, adapting the concept of μTAS and labs-on-a-
chip for cell-based applications has continuously increased to date
(Reichen et al., 2013; Wagner et al., 2013; Frey et al., 2014).
The following section presents a short overview of meth-
ods and material commonly used to design and fabricate lab-
on-a-chip systems for cell analysis. Fabrication methods used
to build lab-on-a-chips systems are based on micro-electro-
mechanical systems (MEMS) technology and include soft lithog-
raphy, hot embossing, injection molding, laser micromachining,
and photolithography as well as more recently introduced three-
dimensional printing techniques (Fiorini and Chiu, 2005; Drag-
one et al., 2013; Ertl et al., 2014). The fabricationmethod of choice
is guided by multiple factors, including available infrastructure
(technology and equipment), fabrication speed, cost (multi-use or
disposable devices), desired feature size, as well as the preferred
fabricationmaterial.While initially glass- and silicon-basedmate-
rials were used to fabricate microfluidic devices (Harrison et al.,
1992; Manz et al., 1992), replica molding has become a dominate
trend in recent years due to its fast and inexpensive fabrication
of microdevices using polydimethylsiloxane (PDMS) (McDonald
and Whitesides, 2002; Zhang et al., 2009, 2010; Berthier et al.,
2012), hydrogels, thermoset composites (Carlborg et al., 2011;
Sollier et al., 2011), and thermoplastics (Duffy et al., 1998; Fiorini
et al., 2003, 2004; Golden and Tien, 2007; Novak et al., 2013).
The application of replica molding, also called “soft lithography”
(Xia and Whitesides, 1998), eliminates the need for time- and
cost-intensive clean room infrastructures. For high-throughput
fabrication of microfluidics, a set of alternative replica molding
procedures are available, including hot embossing and injection
molding. Hot-embossing involves the use of a variety flat ther-
moplastic sheets, such as polymethylmethacrylate (PMMA), poly-
carbonate (PC), cyclic olefin copolymer (COC), polystyrene (PS),
polyvinylchloride (PVC), and polyethyleneterephthalate (PETG)
(Becker and Locascio, 2002; Novak et al., 2013; Ren et al., 2013),
which are molded against a master using pressure and heat
(Locascio et al., 2006). In turn, injection molding involves the
high-pressure injection of pre-polymerized molten thermoplastic
granules into a heated molding cavity (Mair et al., 2006; Attia
et al., 2009), which allows the high-throughput industry-scale
fabrication of thermoplastic devices. A detailed description of
microfabrication methods of lab-on-a-chip devices can be found
elsewhere (Fiorini and Chiu, 2005; Kim et al., 2008a; Coltro et al.,
2010; Sollier et al., 2011; Wu and Gu, 2011).
Apart from the scientific aspects, these fabrication mate-
rials and processes require industrial and clinical compliance
with respect to through-put, biostability, and feasibility. PDMS
microdevices, for instance, cannot be fabricated in a high-
throughput manner, because master molds are mechanically
unstable and therefore the process is inadequate for industrial
applications (van Kan et al., 2012). Furthermore, the disadvan-
tages of PDMS (e.g., hydrophobicity, absorption of molecules tox-
icity of monomers, and vapor permeability) outweigh the advan-
tages frequently reported in the literature (e.g., easy fabrication,
gas permeability, and optical transparency). Even though some of
the materials unpleasantries may be bypassed on a research level
(Sasaki et al., 2010), strategies to date are not fit for industrial scale
fabrication with respect to feasibility, as well as infrastructure and
material costs. Therefore, state-of-the-art industrial fabrication
processes, including hot embossing and injection molding, have
been adopted for low-cost microdevice fabrication to meet the
required production throughput as well as microdevice complex-
ity (Roy et al., 2011, 2015). However, the major disadvantage
of plastic chips is the integration of biosensors (especially metal
electrodes) with only a few processes being fit for industrial
application (Schrott et al., 2009; Huang et al., 2010).
3.2. Liquid Handling Systems for Microfluidic
Cell Cultures
In this section, we review liquid handling systems and compo-
nents for microfluidic cell cultures, including microvalves and
micropumping systems. The main advantage of employing inte-
grated liquid handling systems for cultivation of cell popula-
tions is the ability to continuously supply nutrients and soluble
factors by simultaneously removing waste products, thus pro-
viding a stress free cellular microenvironment for optimum cell
culture conditions. Recent technological advancements in lab-
on-a-chip fabrication has enabled the creation of increasingly
complex devices that include micropumps and valves, mixers,
actuators, degassers, on-chip biosensors, as well as multiple cell
cultivation chambers for multiplexed cell analysis (Reichen et al.,
2013). The technology of handling nano- and picoliter volumes of
fluids started in the 1980s (Whitesides, 2006) and over the years
a variety of different methods and system have been reported
for fluidic actuation and handling (Sackmann et al., 2014). The
most commonly used fluid handling systems for cell cultures are
based on either pressure driven or passive driven flow profiles
using syringe- (Stevens et al., 2008; Sun et al., 2010; Chin et al.,
2011; Song et al., 2014) and electrochemical pumps (Neagu, 1996;
Neagu et al., 1997) as well as gravimetrically (Kim et al., 2008b)
driven flow systems. Overall, the high response time (few sec-
onds) and a very robust and long term reliability and consis-
tency (together with relatively low power consumption) made
syringe pump driven microfluidic systems one of the most com-
monly used for microfluidic cell cultures to date. Nevertheless
the application of microvalves and micropumps to manipulate
and transport solutions at the nanoliter scale (Unger et al., 2000;
Grover et al., 2003; Kim et al., 2012) has opened new opportunities
for improved cell culture handling (Figures 2A–E). For instance,
the integration of computer-controlled pneumatically actuated
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FIGURE 2 | Various types of micropumps for automated and nanoliter liquid handling. (A) Micropumps based on the pneumatic actuation principle
developed by Grover et al. (2003) allowing the pneumatic actuation of the individual pumping chambers via a programmable controller. Reproduced by permission of
by Elsevier (B) shows the schematics of the fluid transport in the micropumps based on the design introduced by Grover et al. (2003). Kindly provided by Novak
(2013), (C) capillary pumps can be actuated by the different geometry and density of post as well as the relative positioning of the channels thus creating different
capillary pressures. For detailed information, see (Zimmermann et al., 2007). Reproduced by permission of The Royal Society of Chemistry. (D) Schematic drawing of
a gravitational-driven pump using the height difference Δh between in- and outlet and thereby controlling the flowrate (Morier et al., 2004). Reprinted with permission
of John Wiley & Sons, Inc. (E) Micropump design proposed by Unger et al. (2000) using a secondary gas-channel layer to control the flow-profile in the underlying
liquid channel. Reprinted by permission of the American Association for the Advancement of Science.
(Figure 2A) micropumps may allow for automation of a num-
ber of crucial liquid handling steps, including cell seeding, flow
direction control, the activation of cells, and their exposure to
bioactive substances at specific solution concentrations. Addition-
ally, passive fluid handling systems for cell cultures rely either
on capillary (Figure 2C) (Zimmermann et al., 2007; Gervais and
Delamarche, 2009) or gravimetrically (Figure 2D) (Morier et al.,
2004) driven flow profiles exhibiting low (fixed) flow rates and
very low response time. Although passive pumping eliminate the
need for additional actuation systems and power consumption,
these fluid handling systems are limited by their consistency and
reusability.
The main advantage of employing on-chip microvalves and
micropumps for quality control measures is that these integrated
microsystems can easily be multiplexed during fabrication and
enable high sample throughput (e.g., microfluidic microarray
technology). Especially, the elimination of dead volumes stem-
ming from tubing, macroscopic valves and fluidic connectors
enables efficient sample and reagent consumption, thus reducing
overall costs. Furthermore, spatio-temporal control over cells and
fluids can be processed in a highly multi-plexed fashion using
fully automated software scripts guaranteeing high reproducibility
while reducing hands-on work, which is prone to user-to-user
variations and failure.
3.3. Integrated Sensing Functions for Microfluidic
Cell Analysis Systems
A major advantage of lab-on-a-chip technology is that it allows
the facile integration of optical, electrical, magnetic, and acousti-
cal sensors for cell analysis (Wu and Gu, 2011). Routinely used
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FIGURE 3 | Different integrable biosensors for cell culture analysis.
(Continued)
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FIGURE 3 | Continued
(A) Schematic cross section of the developed oxygen sensing chip assembly for high resolution oxygen imaging, which can be used to study 2D oxygen distribution
inside microfluidic environments (Ungerböck et al., 2013). Reproduced by permission of The Royal Society of Chemistry. (B) Ratiometric (referenced) image obtained
by division of the red by the green channel. (Ungerböck et al., 2013). Reproduced by permission of The Royal Society of Chemistry. (C) Schematic representation of
organic field-effect transistors (OFETs) for label-free sensing of various chemical/biological species. A detailed description and application can be found elsewhere
(Someya et al., 2010). Reprinted with permission of John Wiley & Sons, Inc. (D) Dual monitoring sensor system for continuous forward light scattering using OPDs
and impedance measurement developed by (Charwat et al., 2013a). Reproduced by permission of The Royal Society of Chemistry. (E) Photograph of fully-spray
coated organic photodetectors (OPDs) developed by Tedde et al. (2009). Reprinted with permission from American Chemical Society. (F) Sketch of the
magnetoresistive-based phagocytosis monitoring methodology developed by Shoshi et al. (2012). Reproduced by permission of by Elsevier.
immunofluorescence end-point analysis can now be extended
with complementary, continuous monitoring techniques (Char-
wat et al., 2013a,b, 2014; Picher et al., 2013; Novak et al., 2015).
Several portable and miniaturized sensors have been developed
over the past years to analyze rapidly changing biological systems.
Among these biosensors optical-based systems, light scattering
(Schafer and Jamieson, 1979; Wilson et al., 2005), absorption-
and transmission- (Jindal and Cramer, 2004) or fluorescence
spectroscopy (Reyes et al., 2002; Hata et al., 2003; Toma et al.,
2011) are predominately used for cell analysis. A detailed review
on integrated on-chip optical detection systems can be found at
Kuswandi et al. (2007). Among cell analysismethods, fluorescence
spectroscopy is still the most widely used optical technique for on
chip cell detection, due to its superior selectivity and sensitivity
and the availability of a broad range of optical labels (Reyes et al.,
2002; Hata et al., 2003). Recently, a variety of integrated optical
oxygen sensors (Schapper et al., 2009) for cell analysis have been
developed for single point measurements (Vollmer et al., 2005;
Lam et al., 2009) and 2D read out systems (Sud et al., 2006; Nock
et al., 2008; Nock and Blaikie, 2010; Thomas et al., 2011; Unger-
böck et al., 2013). For instance, Ungerboek et al. (Ungerböck et al.,
2013) implemented a two-wavelength ratiometric imaging system
(Stich et al., 2009; Wang andMeier, 2010; Larsen et al., 2011; Feng
et al., 2012; Meier and Fischer, 2013) to combine low-cost and
easily available imaging equipment with high-resolution imaging
for oxygen sensing in microfluidic systems (Figures 3A,B). A
CCD camera measuring the intensity at two different wavelengths
of the sensors emitted light by using the different color channels of
the camera one channel providing the oxygen sensitive intensity
image, the other providing a so called reference image, fromwhich
ratiometric calculationswere conducted to accurately detect respi-
ratory activities. Although a variety of excitation sources are avail-
able for fluorescent detection laser-induced fluorescence (LIF) is
most easily adapted to the dimensions of microchips (Auroux
et al., 2002; Gao et al., 2004; Lee and Wen, 2005). Since laser
systems are often expensive and wavelength specific (exhibiting
very narrow bandwidth), a range of alternative light sources,
including organic light-emitting diodes (OLEDs) have been suc-
cessfully integrated into microfluidic devices (Choudhury et al.,
2004; Cai et al., 2008, 2010; Shinar and Shinar, 2008; Liu et al.,
2011; Sagmeister et al., 2013; Williams et al., 2014). Additionally,
organic field-effect transistors (OFETs) (Figure 3C) as read-out
devices for various physical (Sekitani et al., 2009), chemical, and
biological (Lin and Yan, 2012) sensing applications can be used in
the non-invasive, label free analysis system (Someya et al., 2010;
Yun et al., 2014). Furthermore, the latest progress in OFET devel-
opment points at the potential toward the fabrication of a low-cost,
printable, flexible, highly sensitive, and selective detection plat-
form for the integration into LoC analysis and sensor repertoire
(Torsi et al., 2002; Someya et al., 2010). Another recent advance-
ment includes the application of solution-processed fully spray-
coated organic photodiodes (OPDs) (Figure 3E) (Tedde et al.,
2009) for cell analysis, which allows the integration of disposable
fluorescence and chemiluminescence sensors in cartridge-based
analysis systems (Hofmann et al., 2005;Wang andAmatatongchai,
2009; Ryu et al., 2011). To study the electrical properties of
mammalian cells, a variety of electroanalytical methods, such as
voltammetry, potentiometry, and impedance spectroscopy, are
available to provide information of cell viability, proliferation, and
morphology changes. For instance, a current study by Yea et al.
(2013) reported a newly developed electrochemical cyclic voltam-
metry (CV) system to determine the status of mouse embryonic
stem (ES) cells. The proposed electrochemical analysis system
can be applied to an electrical stem cell chip for diagnosis, drug
detection, and on-site monitoring. A powerful non-invasive and
label-free electro-analytical measurement technique to assess cell
morphological changes, migration, stress responses, and differ-
entiation is impedance spectroscopy, mainly known under the
trademark ECIS ™(electrical cell-substrate impedance sensing).
Microfluidic impedance cell cytometry (Sun and Morgan, 2010)
and a great number of impedimetric cell culture analyzers have
been published over the past decade including cytotoxicity (Xiao
and Luong, 2003; Yeon et al., 2005), cell spreading (Wegener et al.,
2000), endothelial cell stimulation and tight junctions (Wegener
et al., 1999) IgE-mediatedmast cell activation (Abassi et al., 2004),
and stem cell differentiation (Cho et al., 2009; Hildebrandt et al.,
2010). Another research group combined two well-established
but usually independently used methods for the label-free anal-
ysis of living cells, impedance spectroscopy, and light scattering
measurement (Charwat et al., 2013a) (Figure 3D). This novel
dual-parameter cell-on-a-chip systemdetects light scattering from
adherent cells providing information on cell number and intracel-
lular granularity and simultaneously performs impedance spec-
troscopy tomonitor cell adhesion and cell–cell interactionwithout
disturbing normal cell behavior wherebymimicking physiological
conditions, such as laminar flow and mechanical stress. Magnetic
detection systems to analyze microfluidic cell cultures in real-
time and label free are among others the magnetic lab-on-a-
chip system (MAGLab) developed by Shoshi et al. (2012). This
high-sensitive device allows the monitoring of phagocytosis in
living cells (Figure 3F) in real time. This combination of mag-
netoresistive sensors, magnetic particles, and microfluidics has
been developed for analyzing the uptake dynamics of the dorsal
cell membrane at different physiological conditions. By tailoring
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the surface bio-chemistry and/or physical characteristics of the
magnetic drug carriers, the developedmethodologymight be used
to analyze the bioavailability of nanodrug carriers in cancerous
cells/tissues, thus improving and expanding the biosensor reper-
toire for cell analysis (Shoshi et al., 2012). In the recent years, the
development and fabrication of magnetic nanoparticles (MNPs)
that can be effectively tailored molecule-specific, magnetism has
become an attractive mechanism for bio-separation and bio-
detection (Pankhurst et al., 2003; Cheon and Lee, 2008; Jun et al.,
2008; Laurent et al., 2008; Gijs et al., 2010). MNPs can selectively
bind to biological entities of interest, including nucleic acids,
proteins, viruses, bacteria, and cells.
After almost half a century of biosensor research with promis-
ing application potential (e.g., agricultural, food and medical
industries), a wide gap between research-based biosensing proof-
of-principle and industrial application still persists. Even though
a few industrial analysis systems have been commercialized so
far, they are mainly confined to electrochemical methods (e.g.,
pH, conductivity, glucose, urea, lactate, etc). The main reason
why only a few biosensors are commercialized to date is the
inflexible and slow technology transfer toward commercialized
products. Even though improvement of sensitivity, selectivity,
and stability is driving the biosensor research field, the lack of
in-line implementation within already existing production pro-
cesses impede the application of microfabricated platforms for
on-chip quality control. For future biosensing platforms to be
able to act as enabling technology especially for the fields of
medical/pharmaceutical diagnostics and quality control, existing
challenges including multiplexed analysis (e.g., sensor arrays),
improved signal-to-noise ratio, probe robustness (e.g., synthetic
alternatives to natural antibodies), non-invasiveness, as well as
sensor platform and assay validation need to be conquered prior
successful application within the biomedical field. Within the area
of cell-based cancer therapeutics, the concept of companion diag-
nostics and precision medicine can potentially be a main driving
force for commercialization of new biosensor products within the
pharmaceutical industry. Nonetheless, a highly interdisciplinary
approach comprising biosensing, multiplexed assays, and minia-
turized automated cell chip technology needs to be approached.
4. Flow Cytometry-on-Chip and Single Cell
Manipulation and Isolation
Since fluorescence-activated cell sorting, commonly known as
flow cytometry (FACS), is extensively used to assess viability,
purity, and potency of cancer vaccines, alternative miniaturized
flow cytometry systems are reviewed in the following sections.
FACS is generally used to analyze sub-populations of a sample
with single cell resolution to obtain information on cell size
(Skierski, 2012) and structural complexity, such as the internal
granularity of cells (Schafer and Jamieson, 1979; Wilson et al.,
2005). Despite the many advantages of FACS techniques, there
are also some drawbacks, such as size of commercially available
flow cytometers, cost of equipment, maintenance, and through-
put capability. The trend toward increased miniaturization has
therefore led to the development of a range of modern cytom-
etry techniques (Cho et al., 2010) (Figure 4A), the so called
μFACS devices that exhibit improved portability and analysis time
FIGURE 4 | Different flow-cytometry cell sorting systems. (A) (Chen
et al., 2009) and (Cho et al., 2010) developed a piezo actuated cell sorting
system for cell separation. The flexible piezo actuator acts as a fast pump
which pushes or pulls the previously detected cell into different sorting
channels enabling the separation of up to 1000 cells/s. Reprinted from Chen
et al. (2009) with permission of Springer Science+Business Media and Cho
et al., 2010 reproduced by permission of The Royal Society of Chemistry.
(B) The micro flow cytometer developed by (Fu et al., 2004) employs
electrokinetic forces rather than the more conventional hydrodynamic forces
technique for flow focusing and sample switching, and incorporates buried
optical fibers for the on-line detection of cells or particles. Reproduced by
permission of by Elsevier. (C) The group of Pamme and Wilhelm (2006)
employed the approach of magnetic cell separation, which is one of the most
efficient methods for bulk cell separation. The on-chip free-flow
magnetophoresis magnetically labeled cells can be separated into
subpopulations of different magnetization with high precision. Reproduced
from Pamme et al. (2006a) by permission of The Royal Society of Chemistry.
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for various medical applications (Fiorini and Chiu, 2005). The
main challenges of μFACS are concerned with miniaturization
and integration of fluidic, optical, and electronic components.
In particular, the reliable generation of disposable microchannel
networks constitutes a fundamental requirement of μFACS appli-
cations for quality control measures for advanced cell thera-
pies (Cvetković and Dittrich, 2013). Recent publications describe
the development of advanced flow cytometry systems involving
electroosmotic (Fu et al., 2004) (Figure 4B), dielectrophoretic
(Lapizco-Encinas, 2004), magnetic (Pamme and Wilhelm, 2006)
(Figure 4C), and hydrodynamic cell sorting application (Bang
et al., 2006). While electroosmotic cell sorting allows precise flow
switching (Fu, 2002; Chen et al., 2009), only low flow rates of
about tens of particles per second can be applied. In turn, dielec-
trophoretic cell sorting allows manipulation and sorting at the
level of single cells, but is characterized by a complex fabrication
and low sensitivity relative to cell differentiation (Chen et al.,
2009). Alternatively, magnetic sorting has become popular in
recent years due to its high selectivity (Chen et al., 2009). Newly
developed methods implement piezoelectric controlled actuators
(Chen et al., 2009) and optical tweezers (Perroud et al., 2008) for
high precision workflow in the μFACS environment. Here, hydro-
dynamically focused cells in the microchannels are selected and
motion controlled by optical tweezers based on their fluorescence
signal. The developed μFCS device by Perround et al. uses an
infrared laser to laterally deflect and control cells into a collection
channel (Perroud et al., 2008). Detection by forward-scattering
and interrogating the signal against LIF allows for precise cell
counting. The selected/labeled cells are captured by the trapping
laser which then manipulates the flow direction into a different
trajectory, thus sorting the cells into separate channels (Ligler
andKim, 2010). The on-chip integration of piezoelectric zirconate
titanate films (PZT) actuators (Chen et al., 2009) inμFACSdevices
allows hydrodynamic focusing of single cells in the sub-nanoliter
volume (Cho et al., 2010) (Figure 4A).When a targeted cell enters
the sorting junction, the PZT actuator is activated using a voltage
pulse to deflect the cell-containing fluid from the center position
toward a side collection channel (Chen et al., 2011), thus enabling
an operating limit of>1000 cells/s. Currently, commercially avail-
able is the miniaturized flow cytometer tabletop-box (NanoCel-
lect, San Diego, CA, USA), which is based on integrated optical
system, the microdevice is combined with PZT actuators (http:
//nanocellect.com/). The current developments in μFACS
devices show good reliability and reasonable throughput to slowly
replace the present conventional large and expensive cytometry
machines.
5. Immunoassay-on-Chip for Quality
Control Applications
Immunoassays are generally used to quantify molecules of bio-
logical interest based on the specificity and selectivity of antibod-
ies against antigens (Cox, 2012). The identification of secreted
biomolecules is also important in cell-based therapies, because
they provide information on the activity of cancer vaccines.
The most commonly employed immunoassays in use today is
the enzyme-linked immunosorbent assay (ELISA) (Engvall and
Perlmann, 1971; Van Weemen and Schuurs, 1971), which was
developed in the 1960s. Since then ELISA has become a funda-
mental tool in biological research and the pharmaceutical industry
(Fossceco et al., 1996; Lequin, 2005). ELISA is predominantly
performed in standard 96-well plate formats which can easily be
automated using standard liquid dispensing systems, robotics, and
colorimetric detectors (Sun et al., 2010). The simplicity, relatively
low cost, and large throughput still place the ELISA as the most
commonly used assays today. Drawback of employing ELISA for
routine quality control measurements for advanced cell therapy
products is its large sample and reagent volumes, its suscepti-
bility to contaminations and lack of providing information on
dynamic changing biological systems. For instance, the time-
dependent release of cytokines by DC can serve as an indicator
of the ability to recruit and activate T-cells in vivo. Here, the
application of microchip technology offers the opportunity to
reduce the costs associated with clinical grade reagents, while
ensuring faster, accurate, and time-resolved analysis (Sun et al.,
2010; Chin et al., 2011; Eyer et al., 2013; Kim and Paczesny,
2013). A number of different ELISA-lab-on-a-chip (ELISA-LoC)
systems with comparable sensitivities were recently designed,
fabricated, and tested for immunological detection (Honda and
Lindberg, 2005; Sista et al., 2008; Lee et al., 2009; Sun et al.,
2010; Kim et al., 2011; Miller and Ng, 2011). A digital microflu-
idic (DMF) device by Miller and Ng (2011) was applied to a
heterogeneous sandwich immunoassay (Figure 5A). The digital
approach to microfluidics manipulates samples and reagents in
the form of discrete droplets, as opposed to the streams of fluid
used in microchannels. Sun et al. (2010) recently showed the
combination of ELISA-LoC devices (Figure 5B) for immunolog-
ical detection of staphylococcal enterotoxin B (SEB). This minia-
turized 96-well ELISA plate, requiring 5μl of sample combined
with a CCD camera allows low-cost immunodetection without
laboratory environment. A microfluidic device for solid-phase
immunoassays based on microparticle labeling was developed by
the group of Kim et al. (2011) for automated sample process-
ing having programmable microvalve controls in a multilayer
structure thus providing automated sample delivery, adjustable
hydrodynamic washing, and compatibility with a wide range of
substrates (Figure 5C). Additionally, Kim and Paczesny (2013)
developed an ELISA-LoC device based on capillary fluid handling
for passive immunoassay automation using multiple reagent and
sample in sequential and parallel manner, thus reducing the total
assay time to ~30min with very low sample volume (Figure 5D).
Another approach for single cell trapping and treatment (e.g.,
washing) prior immunoassays has been introduced by Eyer et al.
(2013) and showed increased repeatability. The cells are controlled
and directed using fluid control and hurdle-microstructures for
individual cell trapping that also increase the overall sensitiv-
ity in detection. Overall, ELISA-LoC devices have increasingly
improved in handling, selectivity, efficiency, and sensitivity, thus
becoming an attractive tool for medicine and biotechnology as
well as the pharmaceutical market. Besides the widely used ELISA
immunoassay, there are also alternative assay formats capable of
detecting biomarkers within a sample. For instance, Cesaro-Tadic
et al. used microfluidic chips to detect the biologically important
cytokine tumor-necrosis-factor-α (TNF-α) using a pre-coated
PDMS surfaces and fluorescently tagged detection antibodies
bound the captured analyte molecules (Cesaro-Tadic et al., 2004).
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FIGURE 5 | Facilitated automated immunoassay on chip. (A) A digital microfluidic (DMF) device by Miller and Ng (2011) was applied to a heterogeneous
sandwich immunoassay. The digital approach to microfluidics manipulates samples and reagents in the form of discrete droplets, as opposed to the streams of fluid
used in microchannels. DMF devices are straightforward to use, and are reconfigurable for any desired combination of droplet operations. This flexibility makes them
suitable for a wide range of applications, especially those requiring long, multistep protocols such as immunoassays. Reprinted from Miller and Ng (2011) with
permission of Springer Science+Business Media. (B) Schematic representation of the 96-well ELISA-LoC system developed by Sun et al. (2010) requires only 5μl
of sample and in the combination with a CCD camera allows low-cost immunodetection without laboratory environment. Reproduced from Sun et al. (2010) by
permission of The Royal Society of Chemistry. (C) The microfluidic device by Kim et al. (2011) for solid-phase immunoassays based on microparticle labeling was
developed using microvalve-control structures for automated sample processing. Programmable microvalve control in a multilayer structure provides automated
sample delivery, adjustable hydrodynamic washing, and compatibility with a wide range of substrates. Reproduced from Kim et al., 2011 by permission of The Royal
Society of Chemistry. (D) Capillarity-driven immunoassay device for sequential and parallel flow processing greatly saving time and labor with an inexpensive setup
developed by Kim and Paczesny (2013). Reprinted with permission from American Chemical Society. (E) Design of the SCBC for single-cell protein secretome
analysis developed by Ma et al. (2011). In their design flow, channels are shown in red and the control channels are shown in blue. An optical micrograph (zoomed
picture) shows the loaded cells isolated within the microchambers, overlaid with the fluorescence micrograph of the developed assay barcode for those same
microchambers. Reprinted by permission from Macmillan Publishers Ltd: Nature Medicine, Ma et al. (2011).
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FIGURE 6 | Schematic illustration of components and systems available to date that can be integrated into a fully automated lab-on-a-chip for cell
culture analysis. Reproduced from Ertl et al. (2014) by permission of by Elsevier.
Additionally, a recently developed method by Junkin and Tay
(2014) enables the detection of cell signaling molecules with high
resolution. Since the most direct way to observe cell activation is
through the detection and quantification of transcription factors,
the microdevices allows direct observation and quantification
using fluorescence microscopy. Furthermore, activation of sin-
gle CD4+ T-cells was studied by Zaretsky et al. (2012) using a
microwell array in combination with fluorescent reporting of the
regulatory T-cell transcription factor Foxp3 and surface staining
of CD69. This LoC system was composed on a thin layer of a
PDMS array of microwells, which can vary in size and depth,
and is placed at the bottom of an optical 96-well plate. T cells
activation and proliferation in the presence of antigen-coated
microbeads was detected using standard optical microscopy. The
microfluidic single-cell barcode chip (SCBC) (Figure 5E) devel-
oped by Ma et al. (2011) detects secreted proteins in a 1 nl
volume microchambers, each loaded with single cells or small
defined numbers of cells. Protein concentrations are measured
with immunosandwich assays from a spatially encoded antibody
barcode. A full barcode represents a complete panel of protein
assays, and duplicate barcodes permicrochamber enablemeasure-
ment statistics at the single-cell level. The SCBC permits on-chip,
highly multiplexed detection of less than 1000 copies of proteins
and requires only ~1 104 cells for the assay (Ma et al., 2011).
The group of Honda and Lindberg (2005) evaluated the com-
mercially available multiple simultaneous immunoassay ELISA-
LoC-CD for easy laboratory integration and ease of handling.
Finally, García et al. (2013) recently developed a micromotor-
based lab-on-chip immunoassays. This innovative LoC system
uses a “on-the-fly” double-antibody sandwich assay (DASA) to
selectively capture target protein, in the presence of excess of non-
target proteins. This nanomotor-based microchip immunoassay
offers many potential applications in clinical diagnostics, envi-
ronmental and security monitoring fields, as well as further
applications in the cell therapy and point-of-care diagnostics
sector.
6. Concluding Remarks and Future
Perspectives
In the advent of personalized cell therapies, the cell manufac-
turing industry will need to manipulate, cultivate, and expand
patient-derived cells in vitro, thus requiring independent manu-
facturing and quality control measures for each patient. In this
case, automation is the most effective strategy to assure repro-
ducibility, which is a core prerequisite of regulating agencies.
Although a number of robotic cell culture systems have been
available for the past 20 years, no automation of quality control
exists, which means that the cost of performing manual quality
control becomes an influencing factor in cell manufacturing. In
fact, regulatory approval may be inhibited by the lack of enabling
technologies for automated quality control to (a) improve repro-
ducibility for assuring compliance with specifications and (b)
reduce hands-on work and corresponding human error. Conse-
quently, translation of lab-on-a-chip technologies in the automa-
tion and miniaturization of quality control procedures is envis-
aged to improve cost effectiveness by reducing expensive clinical
grade biological reagents and labor costs. Although in recent
years a number of commercially available microfluidic systems
have been introduced for cell analysis, their economic success
and market acceptance has been slower than anticipated due to
their unfamiliarity to the users. In summary, the reviewed lab-
on-a-chip technologies containing integrated sensing functions
and automated fluid handling systems have already been success-
fully employed for nucleic acid testing, immunoassays, and cell
analysis.
Consequently, translation of lab-on-a-chip technology in
the automation and miniaturization of quality control proce-
dures is envisaged to improve cost-effectiveness by reducing
expensive clinical grade reagents and hands-on labor costs.
Figure 6 shows a summary of already available lab-on-a-chip
elements for the integration within a single microfabricated plat-
form capable of automated liquid handling, cell propagation,
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and stimulation, and of in-line biosensing and biomolecule anal-
ysis. For instance, the integration of fluid handling systems using
micropumps andmicrovalves is likely to play a critical role in pro-
cess automation because it will enable the programmable trans-
portation and manipulation of microliter to nanoliter volumes
in cell chips with high spatio-temporal precision, thus signifi-
cantly improving assay robustness. Finally, merging of multiple
biosensors and bioassays within one automated platform will be
inevitable for lab-on-a-chip technology to become a competitive
alternative to state-of-the-art industrial quality control measures
of cell-based products and therapeutics.
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